GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Cash And Cash Equivalents

Ablynx NV (XBRU:ABLXS) Cash And Cash Equivalents : €14.95 Mil (As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV Cash And Cash Equivalents?

Ablynx NV's quarterly cash and cash equivalents declined from Dec. 2016 (€53.36 Mil) to Jun. 2017 (€26.39 Mil) but then stayed the same from Jun. 2017 (€26.39 Mil) to Dec. 2017 (€14.95 Mil).

Ablynx NV's annual cash and cash equivalents increased from Dec. 2015 (€3.60 Mil) to Dec. 2016 (€53.36 Mil) but then declined from Dec. 2016 (€53.36 Mil) to Dec. 2017 (€14.95 Mil).


Ablynx NV Cash And Cash Equivalents Historical Data

The historical data trend for Ablynx NV's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Cash And Cash Equivalents Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.53 11.66 3.60 53.36 14.95

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.60 89.88 53.36 26.39 14.95

Ablynx NV Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Ablynx NV  (XBRU:ABLXS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Ablynx NV Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV Business Description

Industry
Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV Headlines

No Headlines